1. Home
  2. INHD vs CMMB Comparison

INHD vs CMMB Comparison

Compare INHD & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Inno Holdings Inc.

INHD

Inno Holdings Inc.

HOLD

Current Price

$1.03

Market Cap

9.6M

Sector

N/A

ML Signal

HOLD

Logo Chemomab Therapeutics Ltd.

CMMB

Chemomab Therapeutics Ltd.

HOLD

Current Price

$1.88

Market Cap

9.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
INHD
CMMB
Founded
2019
2004
Country
Hong Kong
Israel
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.6M
9.1M
IPO Year
2023
2023

Fundamental Metrics

Financial Performance
Metric
INHD
CMMB
Price
$1.03
$1.88
Analyst Decision
Buy
Analyst Count
0
1
Target Price
N/A
$25.00
AVG Volume (30 Days)
157.6K
74.1K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
17.61
101.67
EPS
N/A
0.04
Revenue
$2,846,250.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$45.75
Revenue Growth
221.43
N/A
52 Week Low
$0.06
$0.87
52 Week High
$15.90
$3.86

Technical Indicators

Market Signals
Indicator
INHD
CMMB
Relative Strength Index (RSI) 42.70 56.77
Support Level $1.01 $1.48
Resistance Level $1.17 $2.80
Average True Range (ATR) 0.07 0.18
MACD -0.01 0.05
Stochastic Oscillator 17.61 78.46

Price Performance

Historical Comparison
INHD
CMMB

About INHD Inno Holdings Inc.

Inno Holdings Inc is a building technology company with a mission to transform the construction industry with its proprietary cold-formed steel-framing technology and other innovations. It is a manufacturer of cold-formed-steel members and prefabricated homes. It offers a full range of services required to transform raw materials into precise steel framing products and prefabricated homes. The company sells these finished products either to businesses or directly to customers. The finished products and cold-formed-steel members are used in a variety of building types, including residential, commercial, industrial and infrastructure.

About CMMB Chemomab Therapeutics Ltd.

Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.

Share on Social Networks: